Novo Nordisk H1 2025: Semaglutide Generates $16.6B in Sales, China Revenue Reaches $1.5B

On August 6, Novo Nordisk released 2025H1 Financial Report of the Year, Revenue for the First Half of the Year154.944 billion Danish kroner(Approximately 22.854 billion USD, calculated based on the average exchange rate:1 Danish Krone = 0.1475 US Dollar, hereinafter the same), an increase of 18% year-on-year(Calculated by CER)。Revenue in China: 9.91 billion Danish kroner($1.462 billion), an increase of 6% year-on-yearR&D investment of 21.998 billion Danish kroner, approximately 3.245 billion US dollars.

Source: Novo Nordisk Financial Report

Semaglutide's sales in the first half of the year were112.756 billion Danish kroner (approximately 16.632 billion US dollars), accounting for 73% of Novo Nordisk's total revenue. The sales of this product in the first half of the year have already surpassed Keytruda (USD 15.161 billion), but Eli Lilly's tirzepatide has shown astonishing growth.(Q1 Sales were $6.15 billion, +160%), which might become the biggest competitor for Semaglutide in the race to become the top drug of 2025.

Semaglutide is sold under 3 brand names, specifically:

• Ozempic Injectable for Blood Sugar ReductionSales were 645.20Million Danish Kroner($9.517 billion)）, an increase of 15% year-on-year, with sales in China reaching 2.762 billion Danish kroner($407 million, -5%)。

• Blood Sugar Lowering Oral Version RybelsusSales were 113.48Million Danish Kroner($1.674 billion)）, an increase of 5% year-on-year, with sales in China reaching DKK 116 million($0.17 billion, +7%)。

• Weight-Loss Version of WegovySales amount to368.88Million Danish Kroner($5.441 billion)）, an increase of 78% year-on-year, with sales in China reaching 842 million Danish kroner($124 million)。

In order to further drive performance growth, Novo Nordisk has completed 8 BD deals so far this year, mainly focusing on strengthening its leading position in the cardiovascular-metabolic field.

Source: Insight Database

Novo Nordisk Lowers Its 2025 Performance ForecastIntroduction, revenue is expected to grow 8%-14%.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment options. If you have any needs, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb